News and Trends 8 Mar 2019 HIV Drug Shows Promise for Treating Ulcerative Colitis Patients A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […] March 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 23 Jan 2019 Tackling the Complexity of the Gut Microbiome for Better Treatments An imbalance in gut microbe species is linked with gastrointestinal disease. Philip talked with the CEO and co-founder of the Swiss startup PharmaBiome, Tomas de Wouters, about the complexity of rebalancing the gut microbiome in these conditions. The microbiome is a hugely complex ecosystem of microbes living all around the body. Different parts of the […] January 23, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […] December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 19 Nov 2018 Anti-Inflammatory Treatments Get €40M Boost in Series B A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund clinical trials for anti-inflammatory treatments targeting conditions such as Alzheimer’s and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner […] November 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2018 Septic Shock Drug Shows Promise for Personalized Medicine Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […] October 2, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 24 Aug 2018 Shire gets US market approval for rare inflammatory disease drug The UK-US biotech giant’s drug Takhzyro has been approved by the FDA to prevent attacks of hereditary angioedema, a rare genetic disease that causes swelling around the body. Hereditary angioedema is a potentially life threatening genetic condition that people can inherit from either of their parents. Takhzyro (lanadelumab-flyo) is a first-in-class monoclonal antibody drug that […] August 24, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2018 Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test A blood test developed by Swedish-biotech Immunovia and scientists from Linköping University accurately diagnoses patients with rheumatoid arthritis even if they test negative for two common biomarkers. The current gold standard test for rheumatoid arthritis, which affects 5-7 million people in the US and Europe, misses a substantial number of people who have the condition. […] August 22, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2018 Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results RedHill Biopharma has obtained positive Phase III results for its Crohn’s disease treatment, which targets a certain type of gut bacteria. Crohn’s disease is a type of inflammatory bowel disease, characterized by acute flare-ups and periods of symptom-free remission, that can affect any part of the gastrointestinal tract. It has a high prevalence for an autoimmune disease, […] July 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2018 Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical trials. The treatment uses a bacterium found in the gut to prevent and dampen inflammation. The company, based in Paris, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the […] July 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2018 Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […] June 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2018 German DNA Treatment Reduces Ulcerative Colitis Symptoms Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […] June 6, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email